Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval For Opdivo With Chemotherapy As Neoadjuvant Treatment Of Resectable Non-Small Cell Lung Cancer At High Risk Of Recurrence In Patients With Tumor Cell PD-L1 Expression
Portfolio Pulse from Happy Mohamed
Bristol Myers Squibb (BMY) received a positive CHMP opinion recommending approval for Opdivo with chemotherapy as a neoadjuvant treatment for resectable non-small cell lung cancer in patients with tumor cell PD-L1 expression. The European Commission will now review the recommendation.
May 26, 2023 | 12:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bristol Myers Squibb's Opdivo with chemotherapy received a positive CHMP opinion, potentially leading to approval in the European Union for neoadjuvant treatment of non-small cell lung cancer.
The positive CHMP opinion for Opdivo with chemotherapy is a significant step towards approval in the European Union. If approved, it would be the first and only neoadjuvant immunotherapy-based option authorized to treat patients with non-small cell lung cancer in the EU. This could lead to increased sales and market share for Bristol Myers Squibb, positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100